Navigation Links
Accuray Incorporated to Speak at Oppenheimer Healthcare Conference
Date:10/27/2008

and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 140 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Accuray Incorporated to Report First Quarter Fiscal Year 2009 Financial Results
2. Accuray Incorporated Announces Resignation of Chief Financial Officer
3. Accuray Incorporated to Report Fourth Quarter and Fiscal Year 2008 Financial Results
4. Accuray Incorporateds CEO to Speak at Jefferies Second Annual Healthcare Conference
5. Accuray Incorporateds CEO to Present at Morgan Stanley 2008 Global Healthcare Unplugged Conference
6. Accuray Incorporated to Report Third Quarter Fiscal Year 2008 Financial Results
7. Accurays CFO to Present at B. Riley & Company Ninth Annual Investor Conference
8. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
9. Accuray Reports Continued Growth in Second Quarter of Fiscal 2008
10. Accuray Incorporated to Report Second Quarter Fiscal Year 2008 Financial Results
11. Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... The ... mission control, the surface of a comet, the IceCube observatory at the South Pole, ... way. , The Fall Lecture Series for the world's foremost independently funded research ...
(Date:9/3/2015)... New York, New York (PRWEB) , ... September 03, 2015 , ... ... chief of the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell ... Medical College. , Dr. Winchell is a nationally renowned expert in care for the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic Information ... conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this Sept. ... and Milliman, will discuss how plan sponsors are adopting bold, innovative strategies to ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ProScrub is a ... back & forth, flicker, repeat, and custom speed effects without the use of keyframes. ... speed of effect. ProScrub tools are perfect complements to energetic video productions. ...
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an independent romantic comedy film ... Amazon and will be released on DVD early next year, by Maverick ... Itsuka, an actress and singer/songwriter, and Jason London, lead from “Dazed and Confused.” ...
Breaking Medicine News(10 mins):Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2
... The following is a statement by Lois Aronstein, AARP ... Leader Smith and Assembly Speaker Silver for negotiating a ... one of New York,s most beneficial programs for seniors, ... in danger of losing more than $50 million in ...
... Inc. (NYSE: DST ) has completed the acquisition ... Argus is now a wholly-owned subsidiary of DST. The ... statements respecting DST and its businesses. Such information and comments ... actions or results could differ. There could be a number ...
... Therapeutics, Inc. (Nasdaq: OREX ), a ... today announced that its Board of Directors has ... Officer of the Company, effective immediately. Narachi ... President and CEO. "Michael brings nearly a ...
... Fla., March 31 MSC Care ... and services to post-discharge and post-injury workers, compensation ... Optimal Translation & Transportation, a national company also ... further fortifies MSC,s position in the market, providing ...
... established a link between obesity and the trillions of ... investigating whether the organisms can contribute to the converse: ... Medicine in St. Louis, led by microbiologist Jeffrey Gordon, ... Malawi and Bangladesh have a different mix of intestinal ...
... researchers and private sector biotech scientists will collaborate ... project to discover blood markers that could identify people ... been launched by the Framingham Heart Study. , Researchers ... to Biomarker Research in Cardiovascular Disease, will analyze about ...
Cached Medicine News:Health News:State Budget Preserves State Pharmacy Program for Seniors (EPIC) 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:MSC Acquires Optimal Translation & Transportation 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 3Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 4Health News:Effort Could Lead to Blood Tests for Heart Problems 2
(Date:9/3/2015)... SEATTLE , Sept. 3, 2015  Omeros Corporation ... filed patent infringement lawsuits against Par Pharmaceutical, Inc. and ... the U.S. District Court for the District of ... District Court for the District of Delaware ... Act for Par,s infringement of three Omeros patents, U.S. ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ... the "Investigation Report on China Tamsulosin Market, ... Compared with other a1- adrenergic receptor blockers, ... and lower risk of urinary tract infections and ... its debut in 1993 in Japan ...
(Date:9/3/2015)... Pharma major Lupin Limited ... (Lupin) has launched its Duloxetine 40 mg Delayed-Release ... generic Duloxetine formulation to become available in 40 ... this new strength to market, as it adds ... flexibility of treatment.      (Photo: ...
Breaking Medicine Technology:Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4China Tamsulosin Market Investigation Report 2015 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 3Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 4
... 30, 2011 Company remains committed to ... R&D pipeline boasts 70 potential medicines in clinical development, including ... at least ten potential new medicines in Phase III by the ... therapeutic areas such as neuroscience, diabetes and oncology, as well as ...
... June 29, 2011 OnCore® Software ... Toolkit works with any eIRB system, including commercial and homegrown ... direction between Clinical Trials Management System (CTMS) and eIRB system. ... timely access to both clinical and regulatory data. ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Forte Research Systems Opens Their OnCore Software Developer Toolkit for Use With Any eIRB System 2Forte Research Systems Opens Their OnCore Software Developer Toolkit for Use With Any eIRB System 3
... centrifuges -- the world's most popular Microhematocrit ... one reliable, quiet, compact unit. It is ... separate centrifuges!, For your microcentrifuge needs, order ... you with the MicroMB centrifuge, microcentrifuge rotor ...
... spins up to 25,000 x g for quick and ... ease of use. The Model 5417 C is designed ... cold room and can accommodate a variety of microcentrifuge ... Spin up to 16,400 rpm; 25,000 x g ...
... The Model EXD explosion-proof laboratory floor model ... explosion-proof apparatus. EXD is suitable for use ... all divisions; "atmospheres containing gasoline, petroleum, naphtha, ... Adherence to these specifications is so strict ...
... Oven/Shaker rigidly controls the temperature and ... hybridization and washing steps. This facilitates ... nucleic acids and proteins immobilized on ... radioactive and nonradioactive labeling systems supplied ...
Medicine Products: